BioSpace News Archive

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced the initiation of dosing in a Phase 1 clinical trial evaluating XW014, a novel oral small molecule glucagon-like peptide-1 receptor agonist.

Ascletis Pharma Inc. announces dosing of 24 healthy subjects of the first 3 cohorts in multiple-dose escalation Phase I clinical trial of oral RNA-dependent RNA polymerase inhibitor ASC10 for COVID-19 at the National Medical Center for Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University.

Innovent Biologics, Inc. is pleased to see that the National Medical Products Administration of China has approved the supplemental New Drug Application for CYRAMZA® in patients with hepatocellular carcinoma, who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.

The College of American Pathologists, the world’s largest organization for the medical doctors who diagnose and study disease, recognized several of its members for their contributions to pathology and laboratory medicine during its annual meeting, in New Orleans, Louisiana October 8-11, 2022.

Innovent Biologics, Inc. is pleased to see that the NMPA of China has approved the NDA for selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with a rearranged during transfection gene fusion, adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation who require systemic therapy.

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List by the U.S. Department of Commerce, effective October 7, 2022.